Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3682 - Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride in renal cell carcinoma patients with bone metastases


09 Oct 2016


Poster display


Reza Elaidi


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


R.T. Elaidi1, Y.A. Vano2, N. Aide3, L. Fournier4, D. Deandreis5, F. Tenenbaum6, R. Lebtahi7, H. De Clermont-Galleran8, L. Albiges9, B. Escudier10, F. Joly11, J. Alexandre12, M. Bernardini13, S. Baron14, J. Arfi-Rouche15, C. Noel16, E. Braychenko1, J. O'Quigley17, J. Medioni18, S. Oudard18

Author affiliations

  • 1 Medical Oncology - Hopital Europeen G. Pompidou, ARTIC, 75015 Paris - Paris/FR
  • 2 Medical Oncology, Hopital European George Pompidou, 75015 - Paris/FR
  • 3 Nuclear Medicine, Centre Francois Baclesse, Caen/FR
  • 4 Radiology, European Georges Pompidou Hospital, Paris/FR
  • 5 Nuclear Medicine, Institut G. Roussy, Villejuif/FR
  • 6 Nuclear Medicine, Hôpital Cochin, Paris/FR
  • 7 Nuclear Medicine, Assistance Publique - Hopitaux De Paris, Paris/FR
  • 8 Nuclear Medicine, CHU de Bordeaux Pellegrin, Bordeaux/FR
  • 9 Cancer Medicine, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 10 Medical Oncology, Institut de Cancérologie Gustave Roussy, 94805 - Villejuif/FR
  • 11 Medical Oncology, Centre Francois Baclesse, 14000 - Caen/FR
  • 12 Medical Oncology, Hôpital Cochin, 75014 - Paris/FR
  • 13 Nuclear Medicine, Hopital European George Pompidou, 75015 - Paris/FR
  • 14 Biology, Hopital European George Pompidou, 75015 - Paris/FR
  • 15 Radiology, Institut de Cancérologie Gustave Roussy, 94805 - Villejuif/FR
  • 16 Radiology, Centre Francois Baclesse, Caen/FR
  • 17 Matematic And Statistic, Paris University, Paris/FR
  • 18 Medical Oncology Service, Hopital European George Pompidou, 75015 - Paris/FR


Abstract 3682


Presence of bone metastases (BM) is a factor of poor prognosis in metastatic renal cell carcinoma (mRCC). Radium-223 is a bone targeted active short half-life a-emitter approved in prostate cancer. Its activity in mRCC osteolytic lesions is unknown.

Trial design

The proof of concept study EIFFEL is a French multicentric phase I/II designed to assess the value of Radium-223 for treatment of mRCC bone lesions. Main objective is to identify the most-successful dose among 4 activity levels: 27.5, 55, 82.5, 110KBq/kg. Primary endpoints are the 6 weeks dose-limiting toxicity (DLT) for escalation cohort and conditional efficacy upon whole-body MRI (WB-MRI) and NaF-PET scan for expansion cohort. In order to optimize the precision of the results, 4 innovative methods were implemented in a context of early phases: 1) a continual reassessment model is used for the 2 phases and expected to provide an optimal dose ( most efficient activity given the acceptable toxicity) 2) Radium-223 to DLT causal relationship assessment uses an intrinsic imputability score to avoid confounding adverse events for DLT qualification, 3) a modified RECIST for bone lesions upon WB-MRI and NaF-PET (considering the entire bone metastatic burden) is used to monitor efficacy in the expansion cohort and 4) efficacy data gathered during the escalation phase will provide prior hypothesis to define the optimal efficacy threshold for the expansion cohort. Analysis of correlations between Radium-223 biodistribution scintigraphy, longitudinal WB-MRI, NaF-PET, and circulating bone remodeling markers will further address important questions in clinical, imagery, metabolism and nuclear medicine domains. The EIFFEL study should provide a large amount of useful data for evaluation and treatment of bone metastasis in mRCC. Results of phase I are expected Q1 2018 and Q4 2019 for final phase II results.

Clinical trial identification

EURACT # 2014-003774-16 - CODE: EIFFEL

Legal entity responsible for the study

ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie Siège social : Service de Cancérologie Médicale Hôpital Européen Georges Pompidou 20-30, rue Leblanc, 75908 Paris Cedex 15


Bayer Healthcare


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings